ストックスクリーナーアプリを入手
1.95
0.00%
0.00
前日終値:
$1.95
開ける：
$1.93
24時間の取引高:
94,423
Relative Volume:
0.07
時価総額：
$12.34M
収益：
$93.76M
当期純損益:
$-13.68M
株価収益率:
-0.7414
EPS:
-2.63
ネットキャッシュフロー:
$8.77M
1週間 パフォーマンス:
-2.50%
1か月 パフォーマンス:
+48.85%
6か月 パフォーマンス:
+35.42%
1年 パフォーマンス:
-32.06%
1日の値動き範囲:
$1.91
$1.97
1週間の範囲:
$1.89
$2.2513
52週間の値動き範囲:
$0.95
$2.99
Aytu Biopharma Inc Stock (AYTU) Company Profile
AYTU を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
1.95 | 12.34M | 93.76M | -13.68M | 8.77M | -2.63 |
|
ZTS
Zoetis Inc
|
164.33 | 75.76B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.87 | 49.79B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.20 | 46.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.99 | 20.38B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
283.35 | 14.70B | 2.99B | 1.21B | 1.13B | 25.06 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-05-29 | 開始されました | H.C. Wainwright | Buy |
Aytu Biopharma Inc (AYTU) 最新ニュース
Transcript : Aytu BioPharma, Inc.Special Call - marketscreener.com
Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharma Inc (AYTU) - GuruFocus
Aytu Biopharma chief business officer buys $24,999 in stock By Investing.com - Investing.com South Africa
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock By Investing.com - Investing.com Canada
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock - Investing.com
AYTU BIOPHARMA Executives Increase Stake in Company - TradingView
Aytu BioPharma Announces Closing of Upsized At the Market Public - GuruFocus
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan - ACCESS Newswire
Breakthrough: First Depression Drug Without Sexual Side Effects Gets $16.6M Backing for Q4 Launch - Stock Titan
Aytu BioPharma to commercialise Exxua for MDD in the US - Yahoo Finance
Aytu BioPharma (AYTU) Announces Upsized Public Offering to Fund - GuruFocus
Aytu BioPharma secures exclusive rights to new MDD drug By Investing.com - Investing.com South Africa
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer P - GuruFocus
AYTU Increases Common Stock Offering to 9.6 Million Shares | AYT - GuruFocus
AYTU Increases Common Stock Offering to 9.6 Million Shares | AYTU Stock News - GuruFocus
Aytu BioPharma (AYTU) Secures Exclusive Deal for U.S. Launch of - GuruFocus
Aytu BioPharma secures exclusive rights to new MDD drug - Investing.com
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock | AYTU Stock News - GuruFocus
Aytu BioPharma (AYTU) Secures Exclusive Deal for U.S. Launch of Exxua Tablets | AYTU Stock News - GuruFocus
AytuBioPharma (AYTU) Secures Exclusive Rights to Commercialize EXXUA in the U.S. | AYTU Stock News - GuruFocus
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States | AYTU - GuruFocus
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock - ACCESS Newswire
Aytu BioPharma Secures $14.4M Financing: Major Funds Back EXXUA Depression Drug Commercialization - Stock Titan
New Antidepressant EXXUA Enters $22B Market Without Sexual Side Effects | AYTU Stock News - Stock Titan
AYTU: Lake Street Takes Role as Sole Book-Running Manager | AYTU Stock News - GuruFocus
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Growth in Short Interest - Defense World
Aytu signals ongoing portfolio expansion opportunities as Q3 2025 revenue surges 32% - MSN
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500(TM) - ACCESS Newswire
Aytu BioPharma (AYTU) Reports Significant Revenue Growth in Q3 2 - GuruFocus
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts - MSN
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results | AYTU Stock News - GuruFocus
Aytu BioPharma Inc (AYTU) Q3 2025 Earnings: EPS of $0.21 Beats E - GuruFocus
Why Boot Barn Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Aytu BioPharma Inc (AYTU) Q3 2025 Earnings Call Highlights: Stro - GuruFocus
Aytu BioPharma Reports Strong Q3 2025 Earnings - TipRanks
Aytu Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aytu BioPharma (AYTU) Reports Strong Q3 Earnings Beat - GuruFocus
Earnings call transcript: Aytu BioPharma sees Q3 revenue surge, stock jumps - Investing.com India
Aytu BioPharma Reports Fiscal 2025 Third Quarter Results - TradingView
Transcript : Aytu BioPharma, Inc., Q3 2025 Earnings Call, May 14, 2025 - marketscreener.com
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results - ACCESS Newswire
We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation - simplywall.st
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational a - GuruFocus
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference - ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 - ACCESS Newswire
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27% - simplywall.st
AYTUAytu Biopharma Inc Latest Stock News & Market Updates - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Aytu Biopharma Inc (AYTU) 財務データ
収益
当期純利益
現金流量
EPS
2.54%
大文字化:
|
ボリューム (24 時間):